Recurrent obscure gastrointestinal bleeding: Dilemmas and success with pharmacological therapies. Case series and review

Canadian Journal of Gastroenterology

Volumn 23, Issue 9, 2009, Pages 625-631

  Almadi, Majid ^a   Ghali, Peter M ^b   Constantin, Andre ^a   Galipeau, Jacques ^a   Szilagyi, Andrew ^a  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Obscure gastrointestinal bleed; Pharmacological therapy

Indexed keywords

ANTITHROMBOCYTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; IRON; LONG ACTING DRUG; OCTREOTIDE; PROSTAGLANDIN E2; PROTON PUMP INHIBITOR; THALIDOMIDE; TRANEXAMIC ACID; WARFARIN; ANGIOGENESIS INHIBITOR; ANTIFIBRINOLYTIC AGENT; GASTROINTESTINAL AGENT;

ABDOMINAL CRAMP; ABSENCE OF SIDE EFFECTS; AGED; ANEMIA; ANGIODYSPLASIA; ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; CASE REPORT; CLINICAL TRIAL; COLONOSCOPY; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOW DRUG DOSE; OCCULT BLOOD; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; ANGIOGRAPHY; ANIMAL; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL TRANSPLANTATION; CAPSULE ENDOSCOPY; FATALITY; INSTRUMENTATION; PROSTHESIS; RADIOGRAPHY; RECURRENT DISEASE; SUPERIOR MESENTERIC ARTERY;

AGED; AGED, 80 AND OVER; ANGIODYSPLASIA; ANGIOGENESIS INHIBITORS; ANGIOGRAPHY; ANIMALS; ANTIFIBRINOLYTIC AGENTS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CAPSULE ENDOSCOPY; COLONOSCOPY; FATAL OUTCOME; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL HEMORRHAGE; GASTROSCOPY; HUMANS; MESENTERIC ARTERY, SUPERIOR; OCTREOTIDE; PROSTHESIS DESIGN; RECURRENCE; THALIDOMIDE; TRANEXAMIC ACID;

EID: 70350464418     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/862816     Document Type: Review

References (49)

1. Raju GS, Gerson L, Das A, Lewis B. American Gastroenterological Association (AGA) Institute medical position statement on obscure gastrointestinal bleeding. Gastroenterology 2007;133:1694-1696
2. Raju GS, Gerson L, Das A, Lewis B. American Gastroenterological Association (AGA) Institute technical review on obscure gastrointestinal bleeding. Gastroenterology 2007;133:1697-1717
3. Carey EJ, Fleischer DE. Investigation of the small bowel in gastrointestinal bleeding-enteroscopy and capsule endoscopy. Gastroenterol Clin N Am 2005;34:719-734 (Pubitemid 41643128)
4. Somsouk M, Gralnek IM, Inadomi JM. Management of obscure occult gastrointestinal bleeding: A cost-minimization analysis. Clin Gastroenterol Hepatol 2008;6:661-670 (Pubitemid 351783443)
5. Cello JP, Grendell JH. Endoscopic laser treatment for gastrointestinal vascular ectasias. Ann Int Med 1986;104:352-354 (Pubitemid 16163613)
6. Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001;121:1073-1079 (Pubitemid 33022086)
7. Szilagyi A, Ghali MP. Pharmacological therapy of vascular malformations of the gastrointestinal tract. Can J Gastroenterol 2006;20:171-178
8. Ioannou GN, Rockey DC, Bryson CL, Weiss NS. Iron deficiency and gastrointestinal malignancy: A population-based cohort study. Am J Med 2002;113:276-280 (Pubitemid 35287292)
9. Imperiale TF, Birgisson S. Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: A meta-analysis. Ann Intern Med 1997;127:1062-1071 (Pubitemid 28012075)
10. Foutch PG. Angiodysplasia of the gastrointestinal tract. Am J Gastroenterol 1993;88:807-818
11. Zuckerman GR, Prakash C, Askin MP, Lewis BS. AGA technical review on the evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology 2000;118:201-221 (Pubitemid 30020389)
12. Foutch PG, Rex DK, Lieberman DA. Prevalence and natural history of colonic angiodysplasia among healthy asymptomatic people. Am J Gastroenterol 1995;90:564-567
13. Boley SJ, Sammartano R, Adams A, DiBiase A, Kleinhaus S, Sprayregen S. On the nature and etiology of vascular ectasias of the colon. Degenerative lesions of aging. Gastroenterology 1977;72:650-660
14. Junquera F, Saperas E, de Torres I, Vidal MT, Malagelada JR. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999;94:1070-1076 (Pubitemid 29173630)
15. Warkentin TE, Moore JC, Anand SS, Lonn EM, Morgan DG. Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired Von Willebrand syndrome. Transfus Med Rev 2003;17:272-286
16. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003;349:343-349 (Pubitemid 36886240)
17. Richter JM, Christensen MR, Colditz GA, Nishioka NS. Angiodysplasia. Natural history and efficacy of therapeutic interventions. Dig Dis Sci 1989;34:1542-1546
18. Lewis BS, Salomon P, Rivera-MacMurray S, Kornbluth AA, Wenger J, Waye D. Does hormonal therapy have any benefit for bleeding angiodysplasia? J Clin Gastroenterol 1992;15:99-103.
19. Barkin JS, Ross BS. Medical therapy for chronic gastrointestinal bleeding of obscure origin. Am J Gastroenterol 1998;93:1250-1254
20. Van Cutsem E, Rutgeerts P, Vantrappen G. Long-term effect of hormonal therapy for bleeding gastrointestinal vascular malformations. Eur J Gastroenterol Hepatol 1993;5:439-443 (Pubitemid 23160994)
21. Van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990;335:953-955 (Pubitemid 20134976)
22. Harrison DF. Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope 1982;92:314-320
23. Harris AG. Somatostatin and somatostatin analogues: Pharmacokinetics and pharmacodynamic effect. Gut 1994;(Suppl 3):S1-S4.
24. Kubba AK, Dallal H, Haydon GH, Hayes PC, Palmer KR. The effect of octreotide on gastroduodenal blood flow measured by laser Doppler flowmetry in rabbits and man. Am J Gastroenterol 1999;94:1077-1082 (Pubitemid 29173631)
25. Scarpignato C, Pelosini I. Somatostatin for upper gastrointestinal hemorrhage and pancreatic surgery. Digestion 1990;60(Suppl 3):1-16.
26. Bensaid M, Tahiri-Jouti N, Cambillau C, et al. Basic fibroblast growth factor induces proliferation of a rat pancreatic cancer cell line. Inhibition by somatostatin. Int J Cancer 1992;50:796-799
27. Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Fletcher WS. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 1993;55:446-450 (Pubitemid 23346888)
28. Bowers M, McNulty O, Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with von Willebrand's disease. Br J Haematol 2000;108:524-527 (Pubitemid 30196248)
29. Tulassay Z. Somatostatin and the gastrointestinal tract. Scand J Gastroenterol 1998;33(Suppl 228):115-121
30. Pennazio M, Arrigoni A, Rossini FP. Diagnostic yield and therapeutic implications of push enteroscopy in patients with obscure gastrointestinal bleeding. Am J Gastroenterol 1995;90:1632. (Abst)
31. Gonzalez D, Elizondo BJ, Haslag S, et al. Chronic subcutaneous octreotide decreases gastrointestinal blood loss in blue rubber-bleb nevus syndrome. J Pediatr Gastroenterol Nutr 2001;33:183-188 (Abst) (Pubitemid 32802818)
32. Junquera F, Saperas E, Videla S, et al. Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. Am J Gastroenterol 2007;10:254-260 (Pubitemid 46160536)
33. Orsi P, Guatti-Zuliani C, Okolicsanyi L. Long-acting octreotide is effective in controlling rebleeding angiodysplasias of the gastrointestinal tract. Dig Liv Dis 2001;33:330-334 (Pubitemid 32537019)
34. Scaglione G, Pietrini L, Russo F, et al. Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia. Aliment Pharmacol Ther 2007;26:935-942 (Pubitemid 47346712)
35. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-254
36. Sorrentino P, Parantino G, Conca P, Perrella A. Should octreotide be used cautiously in liver cirrhosis with concomitant congestive heart failure correlated to coronary artery disease? Dig Dis Sci 2003;48:1919.
37. Jenkins SA, Shields R, Davies M, et al. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997;41:526-533 (Pubitemid 27448787)
38. Van Cutsem E, Piessevaux H. Pharmacologic therapy of arteriovenous malformations. Gastrointest Endosc Clin North Am 1996;6:819-832
39. Sabba C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:926. (Pubitemid 34940839)
40. Vujkovac B, Lavre J, Sabovic M. Successful treatment of bleeding from colonic angiodysplasias with tranexamic acid in a hemodialysis patient. Am J Kidney Dis 1998;31:536-538 (Pubitemid 28124111)
41. Saba HI, Morelli GA, Logrono LA. Brief report: Treatment of bleeding hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med 1994;330:1789-1790 (Pubitemid 24177614)
42. Bauditz J, Lochs H. Angiogenesis and vascular malformations: Antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007;13:5979-5984 (Pubitemid 350238263)
43. Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol 2003;98:221-222
44. Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 2004;53:609-612 (Pubitemid 38372989)
45. Bauditz J, Lochs H, Voderholzer W. Macroscopic appearance of intestinal angiodysplasia under antiangiogenic treatment with thalidomide. Endoscopy 2006;10:1036-1039 (Pubitemid 44615243)
46. Dunne KA, Hill J, Dillon JF. Treatment of chronic transfusion-dependent gastric antral vascular ectasia (watermelon stomach) with thalidomide. Eur J Gastroenterol Hepatol 2006;18:455-456
47. Dabak V, Kuriakose P, Kamboj G, Shurafa M. A pilot study of thalidomide in recurrent GI bleeding due to angiodyasplasias. Dig Dis Sci 2008;53:1632-1635
48. Heidt J, Langers AM, van der Meer FJ, Brouwer RE. Thalidomide as treatment for digestive tract angiodysplasias. Neth J Med 2006;64:425-428 (Pubitemid 46001912)
49. Hirri HM, Green PJ, Lindsay J. Von Willebrand's disease and angiodysplasia treated with thalidomide. Hemophilia 2006;12:285-286